For patients with type 2 diabetes mellitus, semaglutide is associated with a reduced risk for a first-time Alzheimer disease (AD) diagnosis compared with other antidiabetic medications.

Semaglutide linked to significantly reduced risk, most strongly compared with insulin and most weakly with other GLP-1 RAs. HealthDay News — For patients with type 2 diabetes mellitus ...

The new rules, which cover both TV and radio, instruct drugmakers to use simple, consumer-friendly language when describing ...

It’s hard to remember a time before Ozempic, Wegovy, and other injectable drugs referred to as GLP-1 receptor agonists (that ...

Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have ...

Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have been associated with at least 100 hospitalizations and 10 deaths, the ...

WEDNESDAY, Nov. 13, 2024 (HealthDay News) -- The blockbuster GLP-1 drug semaglutide ( Ozempic, Wegovy) could curb drinking ...

The study adds that “Similar reductions were seen across obesity status, gender, and age groups,” although “further clinical ...

The head of the company that makes the diabetes and obesity drugs Ozempic and Wegovy has warned that compounded versions of ...

In one hand, a slender young woman holds up a bottle of clear liquid. The words “Skinny” and “GLP-1” — a new class of weight loss drugs — are visible on the label. In the other hand, she raises up a ...

Adults with type 2 diabetes who were prescribed the GLP-1 RA semaglutide had a significantly lower risk for AD compared with their peers who were prescribed any of seven other antidiabetic ...

“Patients who believe that they’re getting access to a safe product, and they believe they’re getting semaglutide … I know for a fact that they are not getting semaglutide, because there ...